Can I read Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial on EtoBox?

Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial by Yuesong Pan; Xia Meng; Aoming Jin; S. Claiborne Johnston; Hao Li; Philip M. Bath; Xuewei Xie; Jing Jing; Jinxi Lin; Yilong Wang; Xingquan Zhao; Zixiao Li; Yong Jiang; Liping Liu; Hongqin Yang; Jiwei Cheng; Zhimin Wang; Yongjun Wang is a Medicine article available to read on EtoBox.

What is Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial about?

## Importance: Dual antiplatelet therapy (dapt) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (tia) in individuals who carry cyp2c19 loss-of-function (lof) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients. ## Objective: To obtain time-course estimates of efficacy and risk with ticagrelor and aspirin after minor stroke or tia in individuals with cyp2c19 lof alleles. ## Design, setting, and participants: The ticagrelor or clopidogrel with aspirin in high-risk patients with acute nondisabling cerebrovascular events ii (chance-2) randomized clinical trial enrolled patients 40 years and older from 202 hospitals in china with acute minor stroke or tia who carried cyp2c19 lof alleles between september 23, 2019, and march 22, 2021, and were followed up for 90 days. all 6412 patients enrolled in the chance-2 trial were included in this secondary analysis. data were analyzed in october 2021. ## Interventions: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2-90) or clopidogrel (300 mg on day 1 followed b

Who reads Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial?

Author

Yuesong Pan; Xia Meng; Aoming Jin; S. Claiborne Johnston; Hao Li; Philip M. Bath; Xuewei Xie; Jing Jing; Jinxi Lin; Yilong Wang; Xingquan Zhao; Zixiao Li; Yong Jiang; Liping Liu; Hongqin Yang; Jiwei Cheng; Zhimin Wang; Yongjun Wang

Publisher

American Medical Association (AMA)

Published

2022

Language

EN

Field

Medicine (Health Sciences)